NCT02759640View on ClinicalTrials.gov

A Phase I Trial of HS-10241 in Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

March 31, 2018

Study Completion Date

May 31, 2018

Conditions
NeoplasmSolid Tumors
Interventions
DRUG

HS-10241

HS-10241 is administered orally starting at 100 mg/day.

Trial Locations (2)

2050

Chris O'Brien Lifehouse, Camperdown

2170

Liverpool, Liverpool

All Listed Sponsors
lead

Atridia Pty Ltd.

INDUSTRY

NCT02759640 - A Phase I Trial of HS-10241 in Solid Tumors | Biotech Hunter | Biotech Hunter